Tirzepatide Plateau: Why the Weight-Loss Curve Flattens
A plateau is the expected shape of the curve on tirzepatide. Here is when it showed up in the trials, how much loss came after it, and what happened to people who stopped.
Code HIGHPEPTIDES takes 15% off at checkout: $80.75
Affiliate link: HighPeptides earns a commission on orders. Research use only. Educational content, not medical advice.
Still logging injections in your Notes app?
A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.
Why does tirzepatide weight loss slow down?
In a 52-week study that estimated energy intake with a mathematical model from body-weight changes during drug-driven weight loss, each kilogram lost raised eating by about 100 kcal per day above baseline, more than three times the drop in energy expenditure (PMID 27804272). That study used canagliflozin, not tirzepatide, so treat it as the general physiology of a plateau rather than a tirzepatide-specific number.
The Lilly post hoc analysis defined a plateau as less than 5% weight change over a 12-week window and every 12-week window after it (PMID 39800653). Weight can still drift down inside that definition, and the authors note that loss at the plateau was slightly lower than the end-of-study loss.
SURMOUNT-1, the main obesity trial, gave tirzepatide once weekly with a 20-week dose escalation (PMID 35658024). In the post hoc analysis, people on 10 or 15 mg, younger people, and women were more likely to reach their plateau later (PMID 39800653).
Median time to plateau was 24.3 weeks for people starting in the overweight range and 36.1 weeks for BMI class II and III (PMID 39800653). People with a higher starting BMI took longer to reach the plateau.
What the Data Shows
After week 36: stay on it or stop?
SURMOUNT-4 put everyone on tirzepatide (10 or 15 mg, the highest dose each person tolerated) for 36 weeks, then randomized 670 people to keep going or switch to placebo for 52 more weeks. This is the trial behind the "21% by week 36, 5.5% more, 14% regain" numbers that circulate on X, and those figures match the paper (PMID 38078870).
| SURMOUNT-4 phase | Stayed on tirzepatide | Switched to placebo |
|---|---|---|
| Weeks 0 to 36 (everyone on open-label tirzepatide) | Mean loss 20.9% for those who completed the lead-in | Same pooled 20.9% lead-in (the two arms split only at week 36) |
| Weeks 36 to 88 | -5.5% (further loss) | +14.0% (regain) |
| Weeks 0 to 88, overall | -25.3% | -9.9% |
| Kept at least 80% of the lead-in loss at week 88 | 89.5% | 16.6% |
Staying on the drug after week 36 still produced a further 5.5% loss, not a reversal. Stopping is what reversed the curve.
Where the curve flattened in each SURMOUNT trial
Different populations land at different heights. People with type 2 diabetes lost less in SURMOUNT-2 than people without diabetes did in SURMOUNT-1, so compare yourself with the right row.
| Trial | Who was in it | Mean weight change on tirzepatide |
|---|---|---|
| SURMOUNT-1, 72 weeks | Obesity or overweight, no diabetes | -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs -3.1% placebo |
| SURMOUNT-1, 176 weeks | Subgroup with obesity and prediabetes | -12.3% (5 mg), -18.7% (10 mg), -19.7% (15 mg) vs -1.3% placebo |
| SURMOUNT-2, 72 weeks | Obesity or overweight with type 2 diabetes | -12.8% (10 mg), -14.7% (15 mg) vs -3.2% placebo |
| SURMOUNT-3, 72 weeks | Started after losing at least 5% on a 12-week intensive lifestyle program | -18.4% additional (from randomization) vs +2.5% placebo |
Sources: SURMOUNT-1 (PMID 35658024), SURMOUNT-1 three-year obesity and diabetes prevention analysis (PMID 39536238), SURMOUNT-2 (PMID 37385275), SURMOUNT-3 (PMID 37840095).
Key Takeaways
- Among adherent SURMOUNT-1 participants who lost at least 5%, 87.6% to 90.2% had reached a plateau by week 72, depending on BMI category (PMID 39800653).
- Median time to plateau ran from 24.3 weeks (overweight) to 36.1 weeks (BMI class II and III), counted from randomization and including the dose-escalation period (PMID 39800653).
- Staying on tirzepatide after week 36 in SURMOUNT-4 added a further 5.5% loss by week 88; switching to placebo led to 14.0% regain (PMID 38078870).
- 89.5% of people who continued kept at least 80% of their lead-in loss, compared with 16.6% on placebo (PMID 38078870).
- In the SURMOUNT-1 prediabetes subgroup treated for 176 weeks, mean loss at 176 weeks was 19.7% at 15 mg (PMID 39536238), close to the 20.9% reported at 72 weeks for the full trial (PMID 35658024). These are different groups, so it is not a direct comparison.
- After withdrawal, waist circumference, blood pressure, HbA1c and non-HDL cholesterol worsened more in people who regained more weight (PMID 41284285).
- No SURMOUNT trial tested what to do at a plateau (diet changes, training, switching drugs). The plateau analysis only described timing.
- The "plateau" date depends on the cutoff the analysts chose (under 5% per 12 weeks). A stricter or looser cutoff would move it.
- The plateau and long-term regain analyses (PMIDs 39800653, 42831032) were limited to adherent people who had already lost at least 5%, so they describe responders, not everyone who starts. The SURMOUNT-4 cardiometabolic analysis (PMID 41284285) looked only at people who lost at least 10% by week 36 and were then switched to placebo.
- The 100 kcal per kg appetite figure comes from a canagliflozin study; nobody has published the equivalent number for tirzepatide.
- Trial doses stopped at 15 mg. There is no published evidence on going beyond that to push past a plateau.
- Trial results may not carry over to compounded or research-grade tirzepatide, whose purity and dosing are not trial-controlled.
Frequently Asked Questions
When does tirzepatide weight loss plateau?
In a post hoc analysis of SURMOUNT-1, median time to plateau was 24.3 weeks for people starting overweight, 26.0 weeks for class I obesity, and 36.1 weeks for class II and III. By week 72, roughly 88% to 90% of adherent responders had plateaued. A plateau there meant under 5% change per 12 weeks (PMID 39800653).
Does tirzepatide stop working once weight loss slows?
The trial data says no. In SURMOUNT-4, people who stayed on 10 or 15 mg after a fixed 36-week lead-in lost a further 5.5% by week 88, and 89.5% kept at least 80% of their earlier loss. Continued treatment held the earlier loss and added to it (PMID 38078870).
What happens if you stop tirzepatide?
SURMOUNT-4 switched people at a fixed week 36, not at a personal plateau. In those switched to placebo, mean weight rose 14.0% from week 36 to week 88, and only 16.6% kept at least 80% of their lead-in loss. A follow-up analysis found systolic blood pressure, waist size, HbA1c and non-HDL cholesterol worsened more in those who regained the most (PMIDs 38078870, 41284285).
Why does weight loss slow down on tirzepatide?
Part of it is the body defending its weight. A study of canagliflozin, a sodium glucose co-transporter inhibitor that causes weight loss by increasing urinary glucose excretion, used a mathematical model to estimate that appetite rises about 100 kcal per day for each kilogram lost, more than three times the drop in energy burned (PMID 27804272). How strongly that feedback acts on tirzepatide has not been measured in the SURMOUNT papers.
Does a higher tirzepatide dose delay the plateau?
In SURMOUNT-1, people on 10 or 15 mg tended to reach their plateau later than those on 5 mg, and they lost more overall: 19.5% and 20.9% at 72 weeks versus 15.0% at 5 mg (PMIDs 39800653, 35658024). That is an association across randomized dose groups. Dose changes are a decision for your prescriber.
Is some regain from my lowest weight normal on tirzepatide?
In a SURMOUNT-1 post hoc analysis of adherent people with prediabetes, mean regain from lowest weight to week 176 was 3.7 to 4.4 kg by dose. 70% regained under 5%, 22% regained 5% to under 10%, and 8% regained 10% or more, while blood sugar gains largely held (PMID 42831032).
Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify). HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links support HighPeptides at no extra cost.
Related HighPeptides Research
Peer-Reviewed References
67-page guide: protocols, dosing, sourcing. Everything in one place.
Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →Educational purposes only. Not medical advice.
Tirzepatide is a prescription medication. Talk to a licensed clinician before starting, stopping, or changing a dose.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.